Skip to main content
Article thumbnail
Location of Repository

GLP-1 based therapeutics: Simultaneously combating T2DM and obesity

By Kristy M Heppner and Diego ePerez-Tilve

Abstract

Glucagon-like peptide-1 (GLP-1) enhances meal-related insulin secretion, which lowers blood glucose excursions. In addition to its incretin action, GLP-1 acts on the GLP-1 receptor (GLP-1R) in the brain to suppress feeding. These combined actions of GLP-1R signaling cause improvements in glycemic control as well as weight loss in type II diabetes (T2DM) patients treated with GLP-1R agonists. This is a superior advantage of GLP-1R pharmaceuticals as many other drugs used to treat T2DM are weight neutral or actual cause weight gain. This review summarizes GLP-1R action on energy and glucose metabolism, the effectiveness of current GLP-1R agonists on weight loss in T2DM patients, as well as GLP-1R combination therapies

Topics: Insulin, Obesity, CNS, diabetes, GLP-1, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571
Publisher: Frontiers Media S.A.
Year: 2015
DOI identifier: 10.3389/fnins.2015.00092
OAI identifier: oai:doaj.org/article:f89f7166ecd6432f82536f9e8cbfe877
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://doaj.org/toc/1662-453X (external link)
  • http://journal.frontiersin.org... (external link)
  • https://doaj.org/article/f89f7... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.